![Simon Tate](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Simon Tate
Corporate Officer/Principal chez
ICG PLC
Profil
Simon Nicholas Tate was the founder of Convergence Pharmaceuticals Ltd., founded in 2010, where the title held was Director & Chief Scientific Officer from 2010 to 2018.
The current job is Managing Director at ICG Plc, starting in 2021.
Former jobs include Non-Executive Director at Calchan Holdings Ltd. and Calchan Ltd., Independent Director at Climb Bio, Inc. from 2019 to 2025, Vice President & Head-Pain Therapeutic Area at Biogen, Inc., VP-Pain & Epilepsy Discovery Performance Unit at GlaxoSmithKline, Inc., and Venture Partner at Bridge Valley Ventures LLP from 2017 to 2021.
Education includes graduate studies at the University Of Dundee.
Postes actifs de Simon Tate
| Sociétés | Poste | Début |
|---|---|---|
| ICG PLC | Corporate Officer/Principal | 01/01/2021 |
Intermediate Capital Group Plc (Private Equity)
 Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance ICG invests in mid-market companies located across the globe, primarily in Asia-Pacific, Western Europe and North America with an enterprise value of €100 million - €2 billion. The firm focuses across a broad range of sectors and industries. It provides financing in the form of mezzanine, debt and equity for real estate, infrastructure, secondary and buyout capital requirements. The firm acquires minority and control interest. | Private Equity Investor | 20/01/2021 |
Anciens postes connus de Simon Tate
| Sociétés | Poste | Fin |
|---|---|---|
| CLIMB BIO, INC. | Directeur/Membre du Conseil | 27/03/2025 |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures invests in companies located in the UK, Europe and North America. The firm focuses on oncology, neuroscience, immunology and rare diseases therapeutics, pharma/biotech sector. They provide financing for buyout transaction. | Private Equity Investor | 01/01/2021 |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops neuropathic pain products | Fondateur | 12/04/2018 |
Calchan Ltd.
 Calchan Ltd. BiotechnologyHealth Technology Operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain | Directeur/Membre du Conseil | - |
| BIOGEN INC. | Corporate Officer/Principal | - |
Formation de Simon Tate
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
68
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Intermediate Capital Group Plc
 Intermediate Capital Group Plc Investment ManagersFinance Provides asset management services | Finance |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
University Of Dundee
 University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intermediate Capital Group Plc (Private Equity)
Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance ICG invests in mid-market companies located across the globe, primarily in Asia-Pacific, Western Europe and North America with an enterprise value of €100 million - €2 billion. The firm focuses across a broad range of sectors and industries. It provides financing in the form of mezzanine, debt and equity for real estate, infrastructure, secondary and buyout capital requirements. The firm acquires minority and control interest. | Finance |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops neuropathic pain products | Health Technology |
Calchan Holdings Ltd.
 Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops novel oral state-dependent calcium channel (CaV 2.2) modulators for chronic pain | Health Technology |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain | Health Technology |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures invests in companies located in the UK, Europe and North America. The firm focuses on oncology, neuroscience, immunology and rare diseases therapeutics, pharma/biotech sector. They provide financing for buyout transaction. | Finance |
